Boston Trust Walden Corp Has $10.04 Million Position in Amgen Inc. (NASDAQ:AMGN)

Boston Trust Walden Corp reduced its position in Amgen Inc. (NASDAQ:AMGN) by 0.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,537 shares of the medical research company’s stock after selling 243 shares during the quarter. Boston Trust Walden Corp’s holdings in Amgen were worth $10,044,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Capital Performance Advisors LLP acquired a new position in shares of Amgen during the third quarter worth $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the 3rd quarter worth approximately $29,000. Matrix Trust Co acquired a new position in Amgen during the 3rd quarter worth approximately $36,000. Heck Capital Advisors LLC acquired a new position in shares of Amgen during the fourth quarter valued at about $36,000. Finally, Livelsberger Financial Advisory bought a new stake in Amgen during the third quarter worth $56,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on AMGN. Barclays upped their target price on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 price target on shares of Amgen in a report on Friday, January 24th. Piper Sandler Companies reiterated an “overweight” rating and set a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. Citigroup dropped their target price on Amgen from $310.00 to $295.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, Jefferies Financial Group restated a “buy” rating and set a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $314.00.

Amgen Trading Up 1.2 %

Amgen stock opened at $288.87 on Tuesday. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The business’s fifty day simple moving average is $271.06 and its two-hundred day simple moving average is $304.11. The company has a market capitalization of $155.28 billion, a price-to-earnings ratio of 36.99, a price-to-earnings-growth ratio of 2.87 and a beta of 0.56.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.30%. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s payout ratio is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.